NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity, supporting the regulatory advancement of the broad-spectrum antiviral candidate.
NV-387 has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks. The company highlighted that the designation is a significant milestone in its efforts to combat measles, a highly contagious viral disease that has seen resurgences in various regions due to vaccination gaps.
Orphan Drug Designation is granted by the FDA to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. It provides benefits such as tax credits for clinical trial costs, waiver of certain FDA fees, and seven years of market exclusivity upon approval. This can accelerate development and reduce financial burdens for the company.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. NV-387 is its lead drug candidate, a unique broad-spectrum antiviral that has shown effectiveness in animal models against monkeypox, smallpox, and measles, in addition to respiratory viruses like RSV, COVID-19, and influenza. The drug has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and the company is now advancing it into Phase II trials.
The announcement comes amid growing global concern over measles outbreaks. According to the World Health Organization, measles cases surged by 79% in 2022 compared to the previous year, driven by declining vaccination rates. There are currently no specific antiviral treatments approved for measles, making NV-387 a potential breakthrough.
The FDA's Orphan Drug Designation could expedite the development and review process for NV-387. The company noted that it plans to leverage the incentives to accelerate clinical testing and manufacturing scale-up. Investors can find the latest news and updates relating to NNVC in the company's newsroom at https://ibn.fm/NNVC.
This development underscores NanoViricides' commitment to addressing unmet medical needs in infectious diseases. The broad-spectrum nature of NV-387 positions it as a potential tool against multiple viral threats, which could have significant implications for public health preparedness.
